Effectiveness of local anesthetic in controlling abdominal pain in laparoscopic gynecological surgery.

EFFECTIVENESS OF ROPIVACAINE 0.1% INTRAPERITONEAL IN POSTOPERATIVE PAIN CONTROL IN GYNECOLOGIC LAPAROSCOPIC SURGERY "

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-002309-39-ES

Enrollment

Unknown

Registered

2015-06-01

Start date

2016-07-08

Completion date

Unknown

Last updated

2016-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EFECTIVENESS OF ROPIVACAINE 0,1% FOR PAIN CONTROL AFTER LAPAROSCOPIC GYNECOLOGICAL SURGERY

Interventions

Trade Name: Naropin Pharmaceutical Form: Solvent for solution for infusion INN or Proposed INN: ROPIVACAINE CAS Number: 84057-95-4 Concentration unit: % percent Concentration type: equal Concentration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: FEMALES WHO NEED A GYNECOLOGY LAPAROSCOPIC SURGERY FOR BENING DISEASES Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 60 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 14

Exclusion criteria

Exclusion criteria: REFUSE TO PARTICIPATE IN THE TRIAL. OVER 2 HOUR OF SURGERY AND ALLERGY TO ANY MEDICATION THAT IT IS USED.

Design outcomes

Primary

Measure	Time frame
Main Objective: EXTENT OF POSTOPERATIVE PAIN;Secondary Objective: NAUSEA AND VOMITING EARLY MOBILIZATION PAIN AT SEVENTH DAY;Primary end point(s): VISUAL ANALOGIC SCALE;Timepoint(s) of evaluation of this end point: INMEDIATE POSTOPERATIVE, AT 2,12 AND 24 HOURS	—

Secondary

Measure	Time frame
Secondary end point(s): MEDICAL HISTORY;Timepoint(s) of evaluation of this end point: INMEDIATE POSTOPERATIVE, AT 2,12 AND 24 HOURS	—

Countries

Spain

Contacts

Public ContactServicio de Anestesia

Hospital de Galdakao

unai.ortegamera@osakidetza.net34944007030

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026